Cohance Lifesciences Limited
997words
0turns
0analyst exchanges
0executives
Key numbers — 40 extracted
20.19%
. Crore 5 Financial Snapshot FY21 Growth in Revenue Growth in EBITDA Growth in PAT 20.19% 13.75% 14.30% 6 Key Ratios EBIT to Income EBITDA to Income PAT to Income 41.32%
13.75%
5 Financial Snapshot FY21 Growth in Revenue Growth in EBITDA Growth in PAT 20.19% 13.75% 14.30% 6 Key Ratios EBIT to Income EBITDA to Income PAT to Income 41.32% 44.41%
14.30%
ncial Snapshot FY21 Growth in Revenue Growth in EBITDA Growth in PAT 20.19% 13.75% 14.30% 6 Key Ratios EBIT to Income EBITDA to Income PAT to Income 41.32% 44.41% 35.38%
41.32%
20.19% 13.75% 14.30% 6 Key Ratios EBIT to Income EBITDA to Income PAT to Income 41.32% 44.41% 35.38% FY21 7 Financials FY21 Revenue EBIDTA PAT EPS 10,240 8,519 N
44.41%
13.75% 14.30% 6 Key Ratios EBIT to Income EBITDA to Income PAT to Income 41.32% 44.41% 35.38% FY21 7 Financials FY21 Revenue EBIDTA PAT EPS 10,240 8,519 N M S E E P
35.38%
14.30% 6 Key Ratios EBIT to Income EBITDA to Income PAT to Income 41.32% 44.41% 35.38% FY21 7 Financials FY21 Revenue EBIDTA PAT EPS 10,240 8,519 N M S E E P U R N M
47%
FY20 FY21 FY20 FY21 8 Financials FY21 EBITDA Margin (%) PAT Margin (%) 47% 44% 37% 35% FY20 FY21 FY20 FY21 9 Financial Table – Q4 & FY21 Revenue EBITDA EBIT
44%
FY21 FY20 FY21 8 Financials FY21 EBITDA Margin (%) PAT Margin (%) 47% 44% 37% 35% FY20 FY21 FY20 FY21 9 Financial Table – Q4 & FY21 Revenue EBITDA EBITDA Mar
37%
FY20 FY21 8 Financials FY21 EBITDA Margin (%) PAT Margin (%) 47% 44% 37% 35% FY20 FY21 FY20 FY21 9 Financial Table – Q4 & FY21 Revenue EBITDA EBITDA Margin E
35%
FY21 8 Financials FY21 EBITDA Margin (%) PAT Margin (%) 47% 44% 37% 35% FY20 FY21 FY20 FY21 9 Financial Table – Q4 & FY21 Revenue EBITDA EBITDA Margin EBIT E
36.95%
rter ended Year ended 31-Mar-21 31-Dec-20 31-Mar-20 31-Mar-21 31-Mar-20 2,624.63 969.91 36.95% 886.76 33.79% 18.70 83.15 223.54 25.75% 644.52 24.56% 186.66 831.16 31.67% 2.53 3.27
33.79%
r ended 31-Mar-21 31-Dec-20 31-Mar-20 31-Mar-21 31-Mar-20 2,624.63 969.91 36.95% 886.76 33.79% 18.70 83.15 223.54 25.75% 644.52 24.56% 186.66 831.16 31.67% 2.53 3.27 254.56 2,797.7
Advertisement